PRME
Prime Medicine, Inc. · Healthcare · Biotechnology
Momentum-Eingaben (vergleichbare Manager):
Halterbreite +20.0% ·
Aktienfluss +30.0% ·
neue Nettopositionen +16.7%
— Formel
Breite Akkumulation — steigende Anteile bei mehr Haltern
Alle Eigentumszahlen: nur beobachtete 13F-Manager, Stammaktienpositionen, Berichtszeitraum Q3 2025
| Quartal | Inhaber | Δ | Aktien | Gemeldeter Wert | Neu | Ausstiege |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | +1 | 62.17M | $229.38M | +6 | −6 |
| Q1 2026 | 80 | +2 | 55.31M | $192.04M | +9 | −7 |
| Q4 2025 | 78 | 0 | 56.37M | $195.61M | +1 | −1 |
| Q3 2025 | 18 | +3 | 30.74M | $170.29M | +3 | — |
| Q2 2025 | 12 | +1 | 18.57M | $45.87M | +1 | — |
| Q1 2025 | 8 | 0 | 10.06M | $20.03M | +1 | −1 |
| Q4 2024 | 8 | -1 | 11.48M | $33.53M | +2 | −3 |
| Q3 2024 | 8 | -1 | 11.29M | $43.71M | +1 | −2 |
| Q2 2024 | 9 | — | 11.11M | $57.12M | — | — |
| # | Manager | Aktien | Δ Anteile | Wert | Deren Gewichtung | Gehalten | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passiv) | 5.65M | +26.0% | $31.31M | 0.0% | ▲ Add | 2 | SEC ↗ ×8 |
| 2 | ARK Investment Management ✦ | 5.48M | +135.8% | $30.35M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passiv) | 4.92M | +35.7% | $27.27M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 4 | Fidelity (FMR) ✦ | 2.81M | -24.9% | $15.58M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 5 | D. E. Shaw & Co. ✦ | 2.22M | Neu | $12.28M | 0.0% | New | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passiv) | 1.77M | +16.9% | $9.79M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Millennium Management ✦ | 1.42M | +858.5% | $7.86M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (passiv) | 1.30M | +4.6% | $7.18M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 1.13M | +407.9% | $6.29M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 900.14K | +72.6% | $4.99M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 11 | Adage Capital Partners ✦ | 771.36K | Neu | $4.27M | 0.0% | New | 1 | SEC ↗ |
| 12 | Morgan Stanley ✦ | 731.00K | — | $4.05M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 13 | Two Sigma Investments ✦ | 447.67K | +73.2% | $2.48M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 414.21K | -2.4% | $2.29M | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 15 | Goldman Sachs Group ✦ | 410.74K | — | $2.28M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 16 | Wellington Management ✦ | 205.32K | Neu | $1.14M | 0.0% | New | 1 | SEC ↗ ×3 |
| 17 | JPMorgan Chase ✦ | 86.78K | — | $480,750 | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 18 | T. Rowe Price ✦ | 74.50K | +14.1% | $413,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
„Ihre Gewichtung" = Anteil der Position am gemeldeten 13F-Eigenkapitalwert des jeweiligen Managers — das Conviction-Maß. ✦ = kuratorisch ausgewählter Manager.
Neue Käufer
| D. E. Shaw & Co. | $12.28M | 0.0% |
| Adage Capital Partners | $4.27M | 0.0% |
| Wellington Management | $1.14M | 0.0% |
Ausgestiegen
| Keine erfassten Ausstiege in diesem Quartal. |
Marktweiter Kontext: über ALLE 13F-Melder (strukturierte SEC-Daten, Q1 2026): 189 Inhaber, 97.53M Anteile, $314.58M gemeldet. Dies ist ein anderer, älterer Zeitraum als die oben genannten Zahlen des erfassten Universums; beide werden niemals vermischt.
Was die erfassten Halter dieses Wertpapiers am häufigsten sonst noch halten — Zählungen gemeinsamer Eigentümerschaft, keine fundamentalen Zusammenhänge.